Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03320174Phase 2Completed

Long-Term Safety Study of Tafenoquine

Role: lead

NCT06656351Phase 2Recruiting

B-FREE Chronic Babesiosis Study

Role: lead

NCT06207370Phase 2Recruiting

Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis

Role: lead

NCT06478641Unknown

Expanded Use in Persistent (B. Microti) Babesiosis

Role: lead

NCT04533347Phase 2Completed

Tafenoquine in Patients With Mild to Moderate COVID-19

Role: lead

NCT02569827Phase 1Withdrawn

Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore

Role: collaborator

All 6 trials loaded